Globus Medical (NYSE:GMED) Stock Purchased by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Globus Medical, Inc. (NYSE:GMED). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Globus Medical stock on September 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Globus Medical Stock Down 1.3%

Shares of GMED traded down $1.01 during trading hours on Wednesday, reaching $75.31. The company’s stock had a trading volume of 99,340 shares, compared to its average volume of 1,475,331. The company has a 50 day moving average of $78.91 and a two-hundred day moving average of $81.59. The firm has a market cap of $10.11 billion, a price-to-earnings ratio of 19.26, a P/E/G ratio of 1.23 and a beta of 0.96. Globus Medical, Inc. has a 1-year low of $57.67 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, August 6th. The medical device company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The business had revenue of $789.61 million during the quarter, compared to analysts’ expectations of $782.88 million. During the same period last year, the company posted $0.86 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, analysts forecast that Globus Medical, Inc. will post 4.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on GMED. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a report on Friday, September 18th. Truist Financial dropped their price target on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. Wells Fargo & Company cut their price objective on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 10th. Finally, Stifel Nicolaus reduced their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a report on Wednesday, July 8th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Globus Medical currently has an average rating of “Moderate Buy” and a consensus price target of $99.46.

Insiders Place Their Bets

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director owned 25,000 shares in the company, valued at approximately $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James Tobin sold 30,000 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the director owned 15,000 shares in the company, valued at $1,118,700. The trade was a 66.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 18.38% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GMED. Elevation Wealth Partners LLC raised its stake in shares of Globus Medical by 2,178.6% in the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 305 shares during the last quarter. Continuum Advisory LLC bought a new stake in Globus Medical during the 2nd quarter worth approximately $25,000. Summit Securities Group LLC bought a new stake in Globus Medical during the 1st quarter worth approximately $48,000. Root Financial Partners LLC grew its position in Globus Medical by 291.5% during the 1st quarter. Root Financial Partners LLC now owns 779 shares of the medical device company’s stock worth $67,000 after acquiring an additional 580 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Globus Medical by 111.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,199 shares of the medical device company’s stock valued at $103,000 after purchasing an additional 632 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Globus Medical Company Profile

Globus Medical, Inc is a medical device company that develops musculoskeletal solutions for surgeons, hospitals and ambulatory surgery centers. Its primary focus is the design, development and commercialization of products used in spinal surgery, including implants, instruments, navigation systems and robotic-assisted technologies.

The company’s portfolio includes the ExcelsiusGPS robotic navigation platform, Excelsius3D imaging technology, spinal implants and systems for procedures such as deformity correction, degenerative spine treatment and minimally invasive surgery.